Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a high-fat diet

Nutrition Research

Volumn 32, Issue 9, 2012, Pages 701-708

  Poulsen, Morten Møller ^a   Larsen, Jens Ø ^a   Hamilton Dutoit, Stephen ^a   Clasen, Berthil F ^a   Jessen, Niels ^a   Paulsen, Søren K ^a   Kjær, Thomas N ^a   Richelsen, Bjørn ^a   Pedersen, Steen B ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Hepatic triglycerides; High fat; NAFLD; NASH; Rat; Resveratrol; UCP2

Indexed keywords

RESVERATROL; TRIACYLGLYCEROL; UNCOUPLING PROTEIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY FAT; BODY WEIGHT; CONTROLLED STUDY; DIET SUPPLEMENTATION; EUTHANASIA; FATTY LIVER; GENE; GENE EXPRESSION; HISTOPATHOLOGY; LIPID DIET; MALE; MITOCHONDRION; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; UCP2 GENE; UPREGULATION;

ADIPOSE TISSUE; ANIMALS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; DIET, HIGH-FAT; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; FATTY LIVER; ION CHANNELS; LIVER; MALE; MITOCHONDRIAL PROTEINS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, RIBOSOMAL, 18S; STILBENES; TRIGLYCERIDES; UP-REGULATION;

ANIMALIA; RATTUS; RATTUS NORVEGICUS; RODENTIA;

EID: 84867858715     PISSN: 02715317     EISSN: 18790739     Source Type: Journal    
DOI: 10.1016/j.nutres.2012.08.004     Document Type: Article

References (32)

1. Schuppan D., Gorrell M.D., Klein T., Mark M., Afdhal N.H. The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver Int 2010, 30(6):795-808.
2. Grattagliano I., Portincasa P., Palmieri V.O., Palasciano G. Managing nonalcoholic fatty liver disease: recommendations for family physicians. Can Fam Physician 2007, 53(5):857-863.
3. Hashimoto E., Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol 2011, 46(Suppl 1):63-69.
4. Edmison J., McCullough A.J. Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis 2007, 11(1):75-104. ix.
5. Ratziu V., Bonyhay L., Di M.V., Charlotte F., Cavallaro L., Sayegh-Tainturier M.H., et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002, 35(6):1485-1493.
6. Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol 2004, 2(12):1048-1058.
7. Musso G., Gambino R., Cassader M., Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010, 52(1):79-104.
8. Day C.P. Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. Liver Int 2006, 26(9):1021-1028.
9. Tomita K., Oike Y., Teratani T., Taguchi T., Noguchi M., Suzuki T., et al. Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice. Hepatology 2008, 48(2):458-473.
10. Krauss S., Zhang C.Y., Lowell B.B. The mitochondrial uncoupling-protein homologues. Nat Rev Mol Cell Biol 2005, 6(3):248-261.
11. Zhou M., Xu A., Lam K.S., Tam P.K., Che C.M., Chan L., et al. Rosiglitazone promotes fatty acyl CoA accumulation and excessive glycogen storage in livers of mice without adiponectin. J Hepatol 2010, 53(6):1108-1116.
12. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444(7117):337-342.
13. Bujanda L., Hijona E., Larzabal M., Beraza M., Aldazabal P., Garcia-Urkia N., et al. Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol 2008, 8:40.
14. Gomez-Zorita S., Fernandez-Quintela A., Macarulla M.T., Aguirre L., Hijona E., Bujanda L., et al. Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Br J Nutr 2011, 1-9.
15. Shang J., Chen L.L., Xiao F.X., Sun H., Ding H.C., Xiao H. Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol Sin 2008, 29(6):698-706.
16. Salmon D.M., Flatt J.P. Effect of dietary fat content on the incidence of obesity among ad libitum fed mice. Int J Obes 1985, 9(6):443-449.
17. Haugaard S.B., Andersen O., Pedersen S.B., Dela F., Richelsen B., Nielsen J.O., et al. Depleted skeletal muscle mitochondrial DNA, hyperlactatemia, and decreased oxidative capacity in HIV-infected patients on highly active antiretroviral therapy. J Med Virol 2005, 77(1):29-38.
18. Nicklas J.A., Brooks E.M., Hunter T.C., Single R., Branda R.F. Development of a quantitative PCR (TaqMan) assay for relative mitochondrial DNA copy number and the common mitochondrial DNA deletion in the rat. Environ Mol Mutagen 2004, 44(4):313-320.
19. Palsamy P., Subramanian S. Ameliorative potential of resveratrol on proinflammatory cytokines, hyperglycemia mediated oxidative stress, and pancreatic beta-cell dysfunction in streptozotocin-nicotinamide-induced diabetic rats. J Cell Physiol 2010, 224(2):423-432.
20. Olholm J., Paulsen S.K., Cullberg K.B., Richelsen B., Pedersen S.B. Anti-inflammatory effect of resveratrol on adipokine expression and secretion in human adipose tissue explants. Int J Obes (Lond) 2010, 34(10):1546-1553.
21. Kang L., Heng W., Yuan A., Baolin L., Fang H. Resveratrol modulates adipokine expression and improves insulin sensitivity in adipocytes: relative to inhibition of inflammatory responses. Biochimie 2010, 92(7):789-796.
22. Baur J.A., Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006, 5(6):493-506.
23. Cani P.D., Amar J., Iglesias M.A., Poggi M., Knauf C., Bastelica D., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56(7):1761-1772.
24. Hancock C.R., Han D.H., Chen M., Terada S., Yasuda T., Wright D.C., et al. High-fat diets cause insulin resistance despite an increase in muscle mitochondria. Proc Natl Acad Sci U S A 2008, 105(22):7815-7820.
25. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127(6):1109-1122.
26. Puigserver P. Tissue-specific regulation of metabolic pathways through the transcriptional coactivator PGC1-alpha. Int J Obes (Lond) 2005, 29(Suppl 1):S5-S9.
27. Chavin K.D., Yang S., Lin H.Z., Chatham J., Chacko V.P., Hoek J.B., et al. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem 1999, 274(9):5692-5700.
28. Jaburek M., Miyamoto S., Di M.P., Garlid K.D., Jezek P. Hydroperoxy fatty acid cycling mediated by mitochondrial uncoupling protein UCP2. J Biol Chem 2004, 279(51):53097-53102.
29. Harper M.E., Dent R., Monemdjou S., Bezaire V., Van W.L., Wells G., et al. Decreased mitochondrial proton leak and reduced expression of uncoupling protein 3 in skeletal muscle of obese diet-resistant women. Diabetes 2002, 51(8):2459-2466.
30. Li L.X., Skorpen F., Egeberg K., Jorgensen I.H., Grill V. Induction of uncoupling protein 2 mRNA in beta-cells is stimulated by oxidation of fatty acids but not by nutrient oversupply. Endocrinology 2002, 143(4):1371-1377.
31. Regnault T.R., Zhao L., Chiu J.S., Gottheil S.K., Foran A., Yee S.P. Peroxisome proliferator-activated receptor-beta/delta, -gamma agonists and resveratrol modulate hypoxia induced changes in nuclear receptor activators of muscle oxidative metabolism. PPAR Res 2010, 2010:129173.
32. Um J.H., Park S.J., Kang H., Yang S., Foretz M., McBurney M.W., et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010, 59(3):554-563.